Vcanbio Cell & Gene Engineering Corp Current Assets
The Current Assets of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Sep 21, 2026 is 304.24 M CNY. In the previous year, Current Assets was 2.51 B CNY — a change of -87.87% (lower).
Get this data via API
Financial Data API
Current Assets
304.24 MCNY
YoY
-87.87%
Last updated:
The Vcanbio Cell & Gene Engineering Corp Current Assets history
3 Years
10 Years
25 Years
Max
| YEAR | Current Assets | YoY |
|---|---|---|
| 304.24 MCNY | -87.87% | |
| 2.51 BCNY | -2.42% | |
| 2.57 BCNY | +8.12% | |
| 2.38 BCNY | +17.06% | |
| 2.03 BCNY | +2.06% | |
| 1.99 BCNY | +2.79% | |
| 1.94 BCNY | +35.42% | |
| 1.43 BCNY | +62.96% | |
| 876.96 MCNY | +1.16% | |
| 866.93 MCNY | -2.18% | |
| 886.27 MCNY | -8.32% | |
| 966.70 MCNY | +3.63% | |
| 932.84 MCNY | +24.72% | |
| 747.96 MCNY | +16.15% | |
| 643.97 MCNY | +17.29% | |
| 549.04 MCNY | +36.07% | |
| 403.49 MCNY | +20.10% | |
| 335.96 MCNY | +39.34% | |
| 241.11 MCNY | -10.89% | |
| 270.56 MCNY | +10.27% | |
| 245.36 MCNY | -6.00% | |
| 261.03 MCNY | -49.23% | |
| 514.17 MCNY | +36.40% | |
| 376.96 MCNY | -52.97% | |
| 801.57 MCNY | +61.05% | |
| 497.72 MCNY | -21.15% | |
| 631.25 MCNY | +8.21% | |
| 583.34 MCNY | +47.65% | |
| 395.08 MCNY | +23.32% | |
| 320.37 MCNY | +10.21% | |
| 290.69 MCNY | +359.14% | |
| 63.31 MCNY | +110.35% | |
| 30.10 MCNY | +5.19% | |
| 28.61 MCNY | — |
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Current Assets of Vcanbio Cell & Gene Engineering Corp is 304.24 M CNY in 2026.
Current Assets of Vcanbio Cell & Gene Engineering Corp changed from 2.51 B CNY to 304.24 M CNY, representing a -87.87% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Assets Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.
Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Vcanbio Cell & Gene Engineering Corp historically and in real time.
Balance Sheet — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth